Inhibrx Biosciences Inc (INBX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2020 | 06-2020 | 03-2020 | 12-2019 | 09-2019 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 127,669 | 0 | 0 | N/A | 0 |
| Receivables | 964 | 0 | 0 | N/A | 0 |
| TOTAL | $131,850 | $0 | $0 | $N/A | $0 |
| Non-Current Assets | |||||
| PPE Net | 3,274 | N/A | N/A | N/A | N/A |
| Other Non-Current Assets | 8,430 | 0 | 0 | 0 | 0 |
| TOTAL | $11,704 | $N/A | $N/A | $N/A | $N/A |
| Total Assets | $143,554 | $0 | $0 | $N/A | $0 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 15,186 | 0 | 0 | 0 | 0 |
| Accrued Expenses | 11,037 | 0 | 0 | N/A | 0 |
| Other current liabilities | 1,875 | 0 | 0 | N/A | 0 |
| TOTAL | $34,737 | $0 | $0 | $N/A | $0 |
| Non-Current Liabilities | |||||
| Long Term Debt | 9,821 | 0 | 0 | N/A | 0 |
| Deferred Revenues | 5,176 | N/A | N/A | N/A | N/A |
| TOTAL | $17,088 | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $51,825 | $0 | $0 | $N/A | $0 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 37,712 | N/A | N/A | N/A | N/A |
| Common Shares | 4 | 0 | 0 | N/A | 0 |
| Retained earnings | -127,730 | 0 | 0 | N/A | 0 |
| TOTAL | $91,729 | $0 | $0 | $N/A | $0 |
| Total Liabilities And Equity | $143,554 | $0 | $0 | $0 | $0 |